<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: <z:hpo ids='HP_0002863'>Myelodysplastic syndromes</z:hpo> are clonal <z:e sem="disease" ids="C1521860" disease_type="Disease or Syndrome" abbrv="">hematologic disorders</z:e>, expanded from myeloid stem cells </plain></SENT>
<SENT sid="1" pm="."><plain>A primitive immunologic disorder is discussed </plain></SENT>
<SENT sid="2" pm="."><plain>This hypothesis could explain a non-casual association with <z:e sem="disease" ids="C0442893" disease_type="Disease or Syndrome" abbrv="">systemic diseases</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>The aim of our study is to test this hypothesis </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: We retrospectively investigated the data of 60 patients with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (group I) hospitalized in our unit from 1990 to 1999 </plain></SENT>
<SENT sid="5" pm="."><plain>The frequency of systemic disorders was screened and compared to controls (group II) </plain></SENT>
<SENT sid="6" pm="."><plain>Group II consisted of 120 patients matched for age and sex and hospitalized in the same hospital during the same period </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: Sixty patients were included (mean age: 83 years old) </plain></SENT>
<SENT sid="8" pm="."><plain><z:hpo ids='HP_0002863'>Myelodysplastic syndrome</z:hpo> subtypes were <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excessive blasts (52%), <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> (43%) and <z:hpo ids='HP_0001924'>sideroblastic anemia</z:hpo> (5%) </plain></SENT>
<SENT sid="9" pm="."><plain>Fourteen cases of systemic manifestations were reported in group I (23%) and five in the controls (4%) (P &lt; 0.0001) </plain></SENT>
<SENT sid="10" pm="."><plain>Systemic manifestations in group I included <z:hpo ids='HP_0002633'>vasculitis</z:hpo> in six cases (42%), <z:e sem="disease" ids="C0162323" disease_type="Disease or Syndrome" abbrv="">polyarthritis</z:e> in three cases (21%), systemic <z:hpo ids='HP_0011034'>amyloidosis</z:hpo> AA in two cases (14%), <z:e sem="disease" ids="C0032453" disease_type="Disease or Syndrome" abbrv="">relapsing polychondritis</z:e> in one case, <z:hpo ids='HP_0000999'>pyoderma</z:hpo> gangrenosum in one case and <z:hpo ids='HP_0002608'>celiac disease</z:hpo> associated with a systemic <z:hpo ids='HP_0002955'>granulomatosis</z:hpo> in one case </plain></SENT>
<SENT sid="11" pm="."><plain>In the controls, <z:hpo ids='HP_0002633'>vasculitis</z:hpo> was present in four cases and <z:e sem="disease" ids="C0162323" disease_type="Disease or Syndrome" abbrv="">polyarthritis</z:e> in one </plain></SENT>
<SENT sid="12" pm="."><plain>Median age at <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> was not influenced by the association with systemic disorders which, in return, have not influenced the <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo>' subtypes </plain></SENT>
<SENT sid="13" pm="."><plain><z:hpo ids='HP_0002863'>Myelodysplastic syndromes</z:hpo> succeeded to systemic manifestations in 71.4% of cases and could not be attributed to immunosuppressive therapy </plain></SENT>
<SENT sid="14" pm="."><plain>CONCLUSIONS: The association of <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> with systemic manifestations seems not to be casual </plain></SENT>
<SENT sid="15" pm="."><plain>It raises the hypothesis of a primitive immunological disorder in both diseases </plain></SENT>
<SENT sid="16" pm="."><plain>Moreover, the description of two cases of systemic <z:hpo ids='HP_0011034'>amyloidosis</z:hpo> and one case of <z:hpo ids='HP_0000999'>pyoderma</z:hpo> gangrenosum might suggest an additional disorder of macrophages or granular cells </plain></SENT>
</text></document>